- Home
- VSTA vs PLX Comparison
VSTA vs PLX Comparison
Compare VSTA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTA
- PLX
- Stock Information
- Founded
- VSTA 1966
- PLX 1993
- Country
- VSTA Brazil
- PLX Israel
- Employees
- VSTA N/A
- PLX N/A
- Industry
- VSTA Other Consumer Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTA Real Estate
- PLX Health Care
- Exchange
- VSTA Nasdaq
- PLX Nasdaq
- Market Cap
- VSTA 187.6M
- PLX 160.2M
- IPO Year
- VSTA 2020
- PLX 1998
- Fundamental
- Price
- VSTA $2.75
- PLX $2.39
- Analyst Decision
- VSTA Sell
- PLX Strong Buy
- Analyst Count
- VSTA 2
- PLX 1
- Target Price
- VSTA $3.00
- PLX $15.00
- AVG Volume (30 Days)
- VSTA 17.0K
- PLX 634.9K
- Earning Date
- VSTA 03-19-2025
- PLX 03-13-2025
- Dividend Yield
- VSTA N/A
- PLX N/A
- EPS Growth
- VSTA N/A
- PLX N/A
- EPS
- VSTA N/A
- PLX N/A
- Revenue
- VSTA $280,865,717.00
- PLX $45,667,000.00
- Revenue This Year
- VSTA $13.03
- PLX N/A
- Revenue Next Year
- VSTA $9.88
- PLX $63.84
- P/E Ratio
- VSTA N/A
- PLX N/A
- Revenue Growth
- VSTA 6.41
- PLX N/A
- 52 Week Low
- VSTA $1.60
- PLX $0.82
- 52 Week High
- VSTA $4.10
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- VSTA 53.88
- PLX 48.43
- Support Level
- VSTA $2.55
- PLX $2.43
- Resistance Level
- VSTA $2.89
- PLX $2.73
- Average True Range (ATR)
- VSTA 0.16
- PLX 0.13
- MACD
- VSTA -0.02
- PLX -0.04
- Stochastic Oscillator
- VSTA 57.31
- PLX 13.95
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.